NCT01536626已完成不适用
SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 211
- 试验地点
- 1
- 主要终点
- HbA1c (glycosylated haemoglobin)
研究概览
简要总结
This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetic subjects treated with BHI 30
排除标准
- 未提供
研究组 & 干预措施
BIAsp 30 users
干预措施: biphasic insulin aspart 30 (Drug)
结局指标
主要结局
HbA1c (glycosylated haemoglobin)
次要结局
- Number of hypoglycaemic events
- Treatment satisfaction: ITSQ (Insulin Treatment Satisfaction Questionnaire)
- Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01536652Novo Nordisk A/S4,994
已完成
不适用
Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00737776Novo Nordisk A/S1,068
撤回
不适用
A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in AlgeriaDiabetes Mellitus, Type 2NCT03862690Novo Nordisk A/S
已完成
不适用
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00709917Novo Nordisk A/S2,171
已完成
不适用
Switch From Metformin Monotherapy to a Bitherapy With Metformin and RepaglinideDiabetesDiabetes Mellitus, Type 2NCT00745433Novo Nordisk A/S906